{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.9","upperLimit":"86.1","value":"62.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Overall Survival, the percentage of patients alive, is defined from the start date of therapy to the date of death from any cause. Patients alive and those who are lost to follow-up at the time of the final analysis will be censored at the date of the last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in patients with relapsed/refractory CD38 positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of TFH cell origin.","id":"OG000","title":"One Arm"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"The end point will be assessed from the start date of therapy up to 3 months.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Percent probability at 3 months"}